Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Inclusion Criteria: Patients with multiple myeloma eligible for autologous hematopoietic stem cell transplantation; Secretory MM should have measurable markers, including: specific M protein value (≥5g/L)； and/or involved flc ≥100mg/L； and/or measurable extramedullary foci (diameter>1cm on CT); Age ≥ 18 years and ≤ 70 years, male or female; PR and above are obtained after induction therapy according to the IMWG response criteria; Mononuclear cells ≥2×10^8/kg body weight, CD34+ cells≥2×10^6/kg body weight; ECOG 0-2, with life expectance ≥3 months; ALT/AST level ≤2.5 times of the maximum of normal range; total bilirubin≤2 times of normal maximum； Neutrophil count≥ 1.5×10^9/L, platelet count ≥50×10^9/L; Normal Left ventricular ejection fraction , NYHA stage 1, lung function GOLD stage 1; Willing to accept the possibility of potential adverse events and efficacy observation by the investigators; Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial. Exclusion Criteria: With ≥2 degree of peripheral neuropath or with pain; Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed; With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction; Patients in pregnancy or lactation; Allergic constitution or being allergic to any drug within the regimen of the trial; With uncontrolled mental diseases; With active infection; With active hepatitis; HIV positive; History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma; With other conditions that the investigators think unfit for the trial.